TRAW vs. NERV, COCP, TNXP, VAXX, NNVC, AYTU, TLPH, VBIV, INDP, and NRSN
Should you be buying Traws Pharma stock or one of its competitors? The main competitors of Traws Pharma include Minerva Neurosciences (NERV), Cocrystal Pharma (COCP), Tonix Pharmaceuticals (TNXP), Vaxxinity (VAXX), NanoViricides (NNVC), Aytu BioPharma (AYTU), Talphera (TLPH), VBI Vaccines (VBIV), Indaptus Therapeutics (INDP), and NeuroSense Therapeutics (NRSN). These companies are all part of the "pharmaceutical preparations" industry.
Minerva Neurosciences (NASDAQ:NERV) and Traws Pharma (NASDAQ:TRAW) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their institutional ownership, dividends, analyst recommendations, community ranking, profitability, risk, media sentiment, earnings and valuation.
Minerva Neurosciences received 347 more outperform votes than Traws Pharma when rated by MarketBeat users.
Minerva Neurosciences presently has a consensus price target of $7.00, indicating a potential upside of 182.26%. Given Traws Pharma's higher probable upside, analysts clearly believe Minerva Neurosciences is more favorable than Traws Pharma.
In the previous week, Traws Pharma had 1 more articles in the media than Minerva Neurosciences. MarketBeat recorded 2 mentions for Traws Pharma and 1 mentions for Minerva Neurosciences. Minerva Neurosciences' average media sentiment score of 1.00 beat Traws Pharma's score of 0.00 indicating that Traws Pharma is being referred to more favorably in the news media.
34.6% of Minerva Neurosciences shares are held by institutional investors. Comparatively, 8.0% of Traws Pharma shares are held by institutional investors. 6.4% of Minerva Neurosciences shares are held by insiders. Comparatively, 3.3% of Traws Pharma shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.
Minerva Neurosciences has a beta of 0.27, meaning that its stock price is 73% less volatile than the S&P 500. Comparatively, Traws Pharma has a beta of 1.43, meaning that its stock price is 43% more volatile than the S&P 500.
Traws Pharma has higher revenue and earnings than Minerva Neurosciences. Traws Pharma is trading at a lower price-to-earnings ratio than Minerva Neurosciences, indicating that it is currently the more affordable of the two stocks.
Minerva Neurosciences has a net margin of 0.00% compared to Minerva Neurosciences' net margin of -8,033.63%. Traws Pharma's return on equity of 0.00% beat Minerva Neurosciences' return on equity.
Summary
Minerva Neurosciences beats Traws Pharma on 8 of the 14 factors compared between the two stocks.
Get Traws Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for TRAW and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding TRAW and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Traws Pharma Competitors List
Related Companies and Tools
